Clinical Trial Update: Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating aliskiren for proteinuric IgA nephropathy despite angiotensin blockade has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Aliskiren (Aliskiren)

Snippet

Sponsor: The University of Hong Kong | Conditions: IgA Nephropathy | Phase 4 | Status: COMPLETED